Company / Cost of Revenue
Lineage Cell Therapeutics, Inc. Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$334.0K
FY2024
5-year range
$334.0K / $1.4M
FY2020-FY2024
Trend
-50.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 9 years, ranging from $168,000 in FY2018 to $1M in FY2022.
Based on SEC 10-K filings.
$334,000 in FY2024 with a 5-year CAGR of +2.0%.
Improved from $1M to $334,000 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -4.6%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2024, cost of revenue decreased 50.2% year-over-year.
- Peak cost of revenue was recorded in FY2022.
- Lowest cost of revenue in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $334.0K | -50.2% |
| FY2023 | $671.0K | -52.9% |
| FY2022 | $1.4M | +270.4% |
| FY2021 | $385.0K | -6.6% |
| FY2020 | $412.0K | +36.4% |
| FY2019 | $302.0K | +79.8% |
| FY2018 | $168.0K | -84.8% |
| FY2017 | $1.1M | +32.3% |
| FY2016 | $837.0K | +5.5% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026